Advanced cardiac imaging in the spectrum of COVID-19 related cardiovascular involvement

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1879873 since 2022-11-18T12:23:02Z

Published version:
DOI:10.1016/j.clinimag.2022.07.009

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Advanced cardiac imaging in the spectrum of COVID-19 related cardiovascular involvement

**Anna Palmisano, a,b,⁎ Michele Gambardella, b Tommaso D'Angelo, c,d Davide Vignale, a,b Raffaele Ascione, a,e Marco Gatti, f Giovanni Peretto, b,g Francesco Federico, b,h Amar Shah, i and Antonio Esposito a,b**

**Abstract**

Cardiovascular involvement is a common complication of COVID-19 infection and is associated to increased risk of unfavorable outcome. Advanced imaging modalities (coronary CT angiography and Cardiac Magnetic Resonance) play a crucial role in the diagnosis, follow-up and risk stratification of patients affected by COVID-19 pneumonia with suspected cardiovascular involvement. In the present manuscript we firstly review current knowledge on the mechanisms by which SARS-CoV-2 can trigger endothelial and myocardial damage. Secondly, the implications of the cardiovascular damage on patient's prognosis are presented. Finally, we provide an overview of the main findings at advanced cardiac imaging characterizing COVID-19 in the acute setting, in the post-acute syndrome, and after vaccination, emphasizing the potentiality of CT and CMR, the indication and their clinical implications.

**Keywords:** COVID-19, Coronary CT angiography, Cardiac Magnetic Resonance, Pulmonary embolism, Myocarditis, Vaccine

**1. Introduction**

Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic. COVID-19 is caused by the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), that primarily manifests as an interstitial pneumonia and can rapidly progress towards severe acute respiratory distress syndrome [1]. Despite the respiratory system is the primary target, multiorgan involvement frequently occurs. Cardiovascular involvement in COVID-19 is common: an increase in levels of biomarkers of cardiac injury or dysfunction (troponin I and T, creatine kinase-MB, myoglobin, NT-proBNP) is described in up to 40% of cases, especially in patients with cardiovascular risk factors [2] and severe disease 3, 4.

Pre-existing cardiovascular risk factors and the occurrence of acute cardiac injury are both predictors of adverse events 5, 6, being associated to more severe disease and higher mortality rate 1, 3, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16.
The spectrum of SARS-CoV-2 cardiovascular manifestations is wide and encompasses multiple clinical presentations, including acute coronary syndromes (ACS), heart failure, myocarditis, and arrhythmias [17] and the underlying mechanism is complex, multifaceted, and still not completely understood [18].

Cardiac symptoms might persist months after recovery from COVID-19 [19]. The introduction of COVID-19 vaccination has significantly reduced the incidence of severe COVID-19. Nevertheless, several reports have raised concerns about myopericarditis occurrence after different types of COVID-19 vaccines [20], [21], [22].

Advanced cardiac imaging plays a role in diagnosis and risk stratification of COVID-19 patients with cardiovascular complications. CT has a pivotal rule in ruling-out coronary artery disease and pulmonary embolism. Vascular evaluation may be coupled with the assessment of pneumonia severity and to myocardial tissue characterization, excluding myocardial scars [23], [24]. Additionally, CT may provide quantitative information about subclinical comorbidities or COVID-19 related complications capable of improving risk stratification of COVID-19 patients [7], [9], [10], [25], [26], [27], (Fig. 1). Cardiac Magnetic Resonance (CMR) is the imaging of choice for the non-invasive characterization of myocardium, allowing to accurately assess ventricular function, myocardial edema, and myocardial injury. CMR imaging is useful for the non-invasive detection of cardiac alteration related to acute COVID-19, post-acute sequelae, and vaccination [28].
Role of CT and CMR in the diagnostic algorithm of COVID-19 related cardiac complication. After clinical evaluation, patients with chest pain, ST elevation ACS, high pretest probability of CAD and high risk of mortality should be referred to emergent invasive coronary angiography (ICA). Patients with NSTEMI, atypical symptoms and ECG abnormality should be referred to CT. A triple rule-out protocol should be preferred for the simultaneous exclusion of pulmonary embolism (PE) and coronary artery disease (CAD). Patients with obstructive CAD should be referred to ICA for percutaneous intervention (PCI), while patients with non-obstructive CAD to tissue characterization. This could be obtained directly from CT, and in presence of scar and ECV alteration according to multidisciplinary evaluation a diagnostic confirmation with CMR can be performed.

In patients with suspected long COVID-19 syndrome and post-vaccination symptoms, CMR is the first level examination. CT can have a role subsequently in order to exclude chronic PE or obstructive CAD in patients with long COVID-19 syndrome.

In the present manuscript, we aim to provide an overview about indication, potentialities, and main findings of cardiothoracic CT and CMR in the most frequent scenarios of COVID-19 related manifestation.

2. COVID-19 related cardiovascular damage physiopathology

Most frequently, COVID-19 related acute myocardial damage manifestation include [18]: i) right ventricular dysfunction because of COVID-19 associated pulmonary embolism or pulmonary hypertension; ii) acute coronary ischemia because of focal epicardial coronary artery thrombosis (type 1 myocardial infarction) or diffuse myocardial ischemia sustained by extensive microvascular dysfunction, hypoxemia and vasoconstriction due to oxygen demand/supply mismatch (type 2 myocardial infarction) [17, 29, 30], resulting from direct vascular infection, endotheliitis, microvascular remodeling, and thrombosis secondary to a hypercoagulability status; iii) myopericarditis following myocardial cell binding, direct/indirect cell damage due to ACE-2 receptor interaction or cytotoxic damage and microcirculation dysfunction as a result of the so-called cytokine storm; iv) vasoplegic shock due to sepsis and dysregulation of the renin-angiotensin system;

Takotsubo syndrome [31] is also reported and considered to be due to unbalanced sympathetic stimulation.
Additionally, COVID-19 patients may suffer from arrhythmias typically ranging from supraventricular arrhythmias in clinically stable patients [32], to major bradyarrhythmias, such as complete heart block and ventricular tachyarrhythmia in complicated infections 33, 34, triggered by hypoxia, electrolyte derangements, myocardial strain, inflammatory microenvironment and drug side effects [35].

Differently from other cardiotropic viruses, SARS-CoV-2 viral particles have been found inside endothelial cells and cardiac macrophages, but never inside cardiomyocytes 33, 36, 37, 38, while macrophage infiltration, inflammation, and microthrombi were the most common finding at autopsy (48% of cases) [39].

Immune-mediated mechanisms such as molecular mimicry are thought to contribute to persistent cardiac dysfunction due to a chronic and uncontrolled cytokine response also in post-acute and chronic phases.

Cardiac complication according to the stage of the disease is reported in Table 1.
Table 1

Cardiac complication and physiopathology according to the stage of disease.

<table>
<thead>
<tr>
<th>Cardiac complication</th>
<th>Pathophysiology</th>
<th>Time of onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute COVID-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Right ventricular</td>
<td>Pulmonary embolism or pulmonary hypertension for hypercoagulability status, endothelial dysfunction, Hypoxemia and vasoconstriction</td>
<td>From acute symptom onset to symptoms resolution</td>
</tr>
<tr>
<td>dysfunction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Type I myocardial</td>
<td>- Endothelial dysfunction</td>
<td></td>
</tr>
<tr>
<td>infarction</td>
<td>- Hypercoagulability status</td>
<td></td>
</tr>
<tr>
<td>- Type II myocardial</td>
<td>- Endothelial dysfunction</td>
<td></td>
</tr>
<tr>
<td>infarction</td>
<td>- Hypoxemia and vasoconstriction</td>
<td></td>
</tr>
<tr>
<td>- Myocarditis,</td>
<td>- Direct viral injury</td>
<td></td>
</tr>
<tr>
<td>pericarditis</td>
<td>- Cytotoxic damage due to cytokine storm</td>
<td></td>
</tr>
<tr>
<td>- Takotsubo cardiomyopathy</td>
<td>- Unbalanced sympathetic stimulation</td>
<td></td>
</tr>
<tr>
<td>- Arrhythmias</td>
<td>- Hypoxia, electrolyte derangements, myocardial inflammation</td>
<td></td>
</tr>
<tr>
<td>Cardiac post-acute</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Myocarditis</td>
<td>- Chronic inflammatory response for persistent viral reservoirs</td>
<td>3–4 weeks after COVID-19 onset</td>
</tr>
<tr>
<td>- Pericarditis</td>
<td>- Chronic autoimmune inflammation due to molecular mimicry</td>
<td></td>
</tr>
<tr>
<td>- Microvascular</td>
<td>- Endothelial dysfunction</td>
<td></td>
</tr>
<tr>
<td>ischemia and myocardial infarction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SARS-CoV-2 vaccination</td>
<td>- Myocarditis, pericarditis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Delayed hypersensitivity reaction</td>
<td>Within 14 days after second shot</td>
</tr>
<tr>
<td></td>
<td>- Molecular mimicry</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Systemic inflammatory response</td>
<td></td>
</tr>
</tbody>
</table>

3. Cardiac imaging in COVID-19

Transthoracic echocardiography is the first imaging technique used in the diagnostic work-up [40] of COVID-19 patients with suspected cardiovascular involvement providing information directly at bedside.

Bonnemain et al. [41] reviewed 151 articles about echocardiogram in COVID-19 patients and found right ventricle (RV) alteration as the most common finding, with RV dilation in up to 49% of patients and RV systolic dysfunction in up to 40%. RV alterations resulted correlated to the severity of lung involvement and to pulmonary hypertension [41] and were associated to increased level of biomarkers of cardiac injury (troponin and NT-pro-BNP), inflammation (C-reactive protein), and pro-thrombotic status (D-dimer). In a prospective multicenter study in-
cluding 1216 hospitalized acute COVID-19 patients, 55% of them had abnormal echocardiograms, however the underlying cause of alteration was not identified in most cases [42]. Therefore, echocardiography plays a crucial role in selecting patients for advanced cardiac imaging, reducing unnecessary exams and diagnostic delays. The diagnostic flow-chart varied according to national and international guidelines and institution according to local expertise and resource availability [40]. The flow-chart we used is reported in Fig. 1.

However, CT is the imaging modality of choice for the evaluation of cardiothoracic complications related to COVID-19 [43], providing useful information in a short time also in unstable patients, while reducing exposure time of patients and personnel [44, 45].

In a recent position paper, Cosyns et al. [46] stated that the pre-test probability of coronary artery disease may represent the primary guidance in the diagnostic work-up of COVID-19 patients with myocardial injury and that coronary computed tomography angiography (CCTA) should be preferred for patients with low-to-intermediate risk of acute coronary syndrome (ACS) because of its high negative predictive value. However, Stefanini et al. found out that 39% of COVID-19 patients with STEMI had negative invasive coronary angiography (ICA) probably for the higher prevalence of type-2 MI in patients during the acute phase of COVID-19. These data further supported the use of CCTA in COVID-19 patients [47], also having the advantage to simultaneously rule-out coronary artery disease (CAD) and pulmonary embolism (PE) using a triple rule-out scanning protocol [23, 24], and to refine risk stratification of COVID-19 patients with the quantification of coronary artery calcium score (CAC) [7, 9, 10, 16, 25, 48].

CT assessment offers the additional advantage of COVID-19 pneumonia severity assessment [1] and to reveal subclinical CV risk factors such as liver steatosis [49], myosteatosis [50], and epicardial fat volume and attenuation [11, 51]. Finally, CT may offer the opportunity to characterize myocardial scar and extracellular volume fraction (ECV) with the addition of a late contrast enhancement scan [23, 24, 52, 53]. This may be particularly useful and effective especially in the emergency setting [23], providing a full range of diagnosis with a single examination requiring few minutes, without the need of CMR [24] (Fig. 2).

![Computed Tomography in COVID-19](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335398/)

**Fig. 2**

The spectrum of CT potentialities in the setting of COVID-19.
Therefore, a comprehensive CT acquisition protocol in suspected acute myocardial damage should include: i) precontrast CT scan for the assessment of pneumonia severity and calcium score; ii) an angiographic triple rule out scan for exclusion of CAD, PE and acute aortic injury, acquired with retrospective gating in order to obtain multiphase reconstruction (0-90% of R-R interval) for the assessment of wall motion alteration; iii) a late contrast enhancement scan acquired 5 to 10 min after contrast administration for the assessment of myocardial scars and for ECV quantification \textsuperscript{54, 55, 56, 57, 58}. Table 2.
# Table 2

CT protocol in suspected COVID-19 related cardiovascular injury.

<table>
<thead>
<tr>
<th>CT scan</th>
<th>Indication</th>
<th>Parameters</th>
<th>Information</th>
<th>Severity cut-off value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-contrast scan</td>
<td>Pneumonia assessment</td>
<td>Standard</td>
<td>- Pneumonia severity</td>
<td>&gt;50% lung volume&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;1, 27&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Large FOV for pneumonia evaluation</td>
<td>- Coronary artery calcium</td>
<td>&gt;400 AU&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;25&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Total thoracic calcium</td>
<td>≥1068 cc&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Main pulmonary artery diameter/Hypertension</td>
<td>≥31 mm&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;27&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Epicardial adipose tissue attenuation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coronary artery calcium</td>
<td>Cardiac FOV prospective ECG-gated scan at 75% of the R-R interval</td>
<td>- Liver steatosis</td>
<td>≥−96.3 HU&lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;11&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Myo steatosis</td>
<td>≤−40 HU&lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;49&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;34.3 (F) and &lt;38.5 (M) HU&lt;sup&gt;b&lt;/sup&gt; &lt;sup&gt;50&lt;/sup&gt;</td>
</tr>
<tr>
<td>Angiographic scan</td>
<td>Pulmonary embolism</td>
<td>Chest FOV, Single energy or DECT, standard parameters</td>
<td>- Pulmonary artery embolism</td>
<td>Presence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Oligoemia</td>
<td>Presence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- RV dysfunction</td>
<td>RV/LV diameter ratio &gt; 0.9&lt;sup&gt;a&lt;/sup&gt; &lt;sup&gt;26&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>CAD</td>
<td>Cardiac FOV. Retrospective gating with automatic tube current modulation (100% in 60–80% or 40–80% for HR &lt;65 bpm or &gt;65 bpm with 4% current in other phases). 80 kVp for BMI &lt; 20; 100 kVp for BMI ≥ 20 and &lt;30; 120 kVp for BMI ≥ 30</td>
<td>- Obstructive CAD</td>
<td>≥50% &lt;sup&gt;69&lt;/sup&gt; presence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Wall motion abnormalities</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Same for CAD protocol but chest</td>
<td></td>
</tr>
</tbody>
</table>


<sup>a</sup>Cut-off values associated with increased mortality in COVID-19 setting.
Late contrast enhancement scan needs higher contrast volume compared to standard CCTA, with a total iodine dose of 600 mg per kilogram of body weight \(^{55, 59}\).

However, tissue characterization in CT has still limited application worldwide mainly for limited contrast-to-noise ratio, requiring experience for scar detection \(^{55}\), hence CMR remains the gold standard for non-invasive characterization of myocardial tissue. CMR should be considered in COVID-19 patients with high pretest probability for acute myocardial injury, in particular in those with chest pain and unobstructed coronary arteries to differentiate between acute myocarditis, Takotsubo cardiomyopathy, and MINOCA \(^{40, 60, 61}\), avoiding diagnostic and treatment delay.

Several authors \(^{40, 61, 62}\) proposed short CMR protocols to improve resource allocation and to reduce the infection risk (Table 3). A tailored CMR protocol should include cine-sequences for functional assessment, T2-based imaging to evaluate myocardial edema (i.e., T2w-STIR and T2 mapping), and T1-based imaging (i.e., T1 mapping and late gadolinium enhancement evaluation) to evaluate myocardial edema, hyperemia/capillary leak, necrosis, and pre-existing fibrosis. To exclude pulmonary embolism, a 3D pulmonary angiography could be acquired during gadolinium injection \(^{63}\), while, to assess lung pathology, a breath hold T2-w sequence can be used \(^{40}\) Table 3.

### Table 3

<table>
<thead>
<tr>
<th>Timeline</th>
<th>Sequence</th>
<th>Planes and coverage</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Precontrast</td>
<td>Black Blood STIR T2w</td>
<td>Entire ventricle</td>
<td>Edema</td>
</tr>
<tr>
<td></td>
<td>sequence</td>
<td>coverage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>T2 mapping</td>
<td>3 short axis</td>
<td>Edema</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(base, mid, apex)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Native T1 mapping</td>
<td>3 short axis</td>
<td>Edema, fibrosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(base, mid, apex)</td>
<td></td>
</tr>
<tr>
<td>Gadolinium</td>
<td>FLASH 3D pulmonary angiography</td>
<td>3D entire chest</td>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td>injection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2–5 min post</td>
<td>SSFP cine</td>
<td>Entire ventricle</td>
<td>Volume and function</td>
</tr>
<tr>
<td>contrast</td>
<td></td>
<td>coverage</td>
<td></td>
</tr>
<tr>
<td>10 min post</td>
<td>Inversion recovery or 3D-PSIR</td>
<td>Entire ventricle</td>
<td>Myocardial scar</td>
</tr>
<tr>
<td>contrast</td>
<td></td>
<td>coverage</td>
<td></td>
</tr>
<tr>
<td>15 min post</td>
<td>Post-contrast T1 mapping</td>
<td>3 short axis</td>
<td>Extracellular volume</td>
</tr>
<tr>
<td>contrast</td>
<td></td>
<td>(base, mid, apex)</td>
<td>fraction</td>
</tr>
<tr>
<td>Optional</td>
<td>T2w</td>
<td>Chest</td>
<td>Pneumonia</td>
</tr>
</tbody>
</table>

\(^{b}\)Cut-off values derived from population studies or other clinical settings.
Based on the high rate of myocarditis in patients with COVID-19 myocardial injury, mapping techniques are crucial for the identification of subtle myocardial inflammation according to the updated Lake Louise criteria [64], while the evaluation of standard CMR criteria are enough for the identification of Takotsubo cardiomyopathy [65] and MINOCA [66] also in COVID-19 setting.

Main CT and CMR findings according to the stage of disease are reported in Table 4.
### Table 4

Main cardiac complication at CT and CMR according to the stage of disease.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patients (n)</th>
<th>Age (y); male (%)</th>
<th>Follow-up time</th>
<th>Cardiovascular symptom or signs (%)</th>
<th>Main CT findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute cardiovascular complications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV function alterations</td>
<td>Kato et al. [28]</td>
<td>1414</td>
<td>NR; NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Takotsubo cardiomyopathy</td>
<td>Ojha et al. [76]</td>
<td>199</td>
<td>NR; 57</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Esposito et al. [75]</td>
<td>10</td>
<td>52 ± 6; 20</td>
<td>3 (IQR, 2–4) days after symptoms onset</td>
<td>Chest pain (80%)</td>
</tr>
<tr>
<td>Myocardial edema</td>
<td>Ojha et al. [76]</td>
<td>199</td>
<td>NR; 57</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Kato et al. [28]</td>
<td>1414</td>
<td>NR; NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>
| Myocarditis or pericarditis | Pontone et al. [24] | 1 | 59; 1 | 1 day after COVID-19 disease diagnosis | Dyspnea and chest pain | Subepicardial (non-ischemic) late iodine enhancement (LIE) in the basal-mid inferolateral RV: right ventricle; LV: left ventricle; IQR: interquartile range; CI: confidence interval EF: ejection fraction; LGE: late gadolinium enhancement; MACE: major adverse cardiovascular events; IVC: inferior vena cava; ED: emergency department; NR: not reported.
4. Acute cardiovascular damage: the role of CT

Right ventricle dysfunction due to pulmonary embolism or hypertension is the most frequent alteration occurring in the acute setting [41] and CT is indicated to rule-out PE when D-dimer levels are significantly elevated. In COVID-19 patients, PE was found to affect up to 30% of hospitalized patients and to involve vessels mainly located in areas of parenchymal consolidation [67]. Additionally, vessel enlargement within or outside pulmonary opacities, dilated distal sub-segmental vessels touching pleura or fissures, and the mosaic attenuation pattern were reported to be probably related to vascular inflammation, endothelial damage, micro-thrombosis, and dysfunctional vasoregulation [68].

Inflammatory thrombogenic vasculopathy leads to increased pulmonary peripheral resistance and pulmonary hypertension. Enlarged pulmonary artery on CT scan is a biomarker of pulmonary hypertension, and a main pulmonary artery diameter ≥ 31 mm was found to be an independent predictor of COVID-19 outcome [27]. This measurement would be highly reliable compared to the ratio between main pulmonary artery diameter (PA) to aorta calliper (Ao) for the risk of false negative results due to enlarged ascending aorta. The extraction of both these measurements does not require administration of contrast agent and can be obtained from standard non-contrast chest CT performed for lung assessment. On the other hand, CCTA and triple rule-out CT may show ancillary findings suggestive for right ventricle (RV) dysfunction. RV dysfunction is a common occurrence in COVID-19 pneumonia associated to severity of lung involvement and pulmonary hypertension [41]. CT findings suggestive of RV dilation/dysfunction are RV strain (RV to LV diameter ratio > 0.9), septal flattening due to increased RV pressure, and contrast agent reflux in the inferior vena cava (IVC) [26] (Fig. 2). Planek et al. [26] investigated the predictive values of these parameters in a cohort of 245 COVID-19 patients and found that septal flattening and IVC reflux were independently associated with higher risk of 60-day mortality and MACE. All these data are easy to be extracted and should be routinely reported to improve the identification of high-risk patients.

CCTA is indicated in patients with COVID-19 pneumonia with elevated troponin serum levels and non-ST elevation for the exclusion of an ACS [45], reducing useless ICAs. Moreover, because NSTEMI management depends on patients' cardiovascular risk, CCTA can improve risk stratification.

CCTA can quickly rule out or confirm the presence of clinically significant CAD and identify the features of vulnerable plaques, such as low attenuation (<30 HU), positive remodeling, spotty calcifications [69], and napkin-ring sign, becoming an essential tool for selecting patients eligible for invasive imaging [70] or for identifying coronary wall alteration due to COVID-19 related vasculitis [30].

Coronary artery calcium score (CAC) is an established biomarker for risk stratification in patients with suspected CAD and its value has been also documented in COVID-19 setting [25]. Several studies [9, 10, 16, 25] showed that elevated CAC score, specially >400 AU, is associated to poor prognosis. Female patients showed lower mortality compared to men. However, this gender mortality gap disappears in the subgroup of patients with CAC >100 AU [16], suggesting that the differences in outcomes can be at least partially explained by the gender difference in cardiovascular risk profiles and that CAC is a risk modifier. This could be explained by the biological meaning of CAC, being a biomarker of vascular senescence and atherosclerosis, there-
fore suggestive for higher susceptibility to endothelial damage. Additionally, CAC resulted associated to hypertension [7], a comorbidity commonly associated to COVID-19 infection and severity. Moreover, CAC revealed subclinical CAD in COVID-19 patients [9], improving risk stratification. Furthermore, calcium score of the aortic valve, known marker of aortic stenosis, and of the thoracic aorta, marker of atherosclerosis, resulted prognosticators together with CAC 10, 26.

Additionally, from the same CT examination, information about epicardial adipose tissue attenuation (EAT) (Fig. 2, Table 2), a marker of inflammation associated to plaque vulnerability [71] and COVID-19 severity 11, 72 could be extracted.

EAT attenuation ranges between −45 HU and −195 HU while it is increased in case of inflammation [73]. However, different cut-off values were found in previous studies on COVID-19 patients, probably due to methodological issues (e.g., segmentation method, analysis) and to the limited sample size 11, 44, 72.

Vascular evaluation can be combined with the assessment of lung parenchyma, providing information about COVID-19 pneumonia severity and disease stage 1, 74 and identifying other diagnosis responsible of symptoms and laboratory markers alteration.

5. Acute cardiovascular damage: the role of CMR

In May 2020, Sala et al. [31] firstly described cardiovascular involvement studied with CMR and endomyocardial biopsy in a 43-year-old woman affected by COVID-19 with severe myocardial edema and reverse Takotsubo motion pattern, diagnosed as acute myocarditis at histology. Initial reports on COVID-19 patients with acute myocardial injury that underwent CMR 33, 75 showed myocarditis as the most frequent finding, with diffuse myocardial edema and minimal or negligible LGE, followed by Takotsubo cardiomyopathy.

These initial data were confirmed by Ojha et al. [76] that firstly conducted a meta-analysis on COVID-19 patients who underwent CMR. The most common diagnosis (40.2%) in a total of 34 studies and 199 patients was myocarditis, while CMR was negative in 21% of cases, a finding partially due to the time gap between symptoms onset and CMR, which reached up to 71 days. The most common findings were increased T1 (73%) and T2 (63%) myocardial mapping values, with LGE being less common (43%). When present, LGE had non-ischemic pattern involving a few segments with subepicardial distribution (81%) in the inferior/infero-lateral basal segments of the left ventricle.

Kato et al. [28] published an updated meta-analysis in 2022 that included 10,462 COVID-19 patients who underwent CMR and found a minimal reduction in left (−2.84%) and right (−2.69%) ventricular ejection fraction in COVID-19 patients compared to controls, with LV LGE abnormalities in 27.5%, pericardial involvement in 11.9%, T1 mapping alteration in 39.5%, T2 mapping or T2-weighted sequences alterations in 38.1%, with a prevalence of myocarditis of 17.6%.

These confirm that LV involvement is common in COVID-19 patients, CMR is useful in detecting cardiac abnormalities, and myocarditis is the most common finding. It was reported an 18-fold increased risk to develop myocarditis in COVID-19 [13], independently of patients' age, related
to multisystem inflammatory syndrome [13].

Advanced CMR imaging techniques (i.e. mapping techniques) outperform “traditional” techniques such as LGE in COVID-19 patients (Fig. 3) due to the absent or limited necrosis 77, 78.

**Fig. 3**

CMR of acute left ventricle dysfunction during COVID-19. A 39-year-old male presented to the emergency department for fever, cough and dyspnea. Nasopharyngeal swab was positive for SARS-CoV 2 infection. Laboratory tests showed increased troponin T level (42.6 ng/mL, normal value <14 ng/mL) and a moderate depression of left ventricle systolic function (ejection fraction <40%) was documented at echocardiography. CMR was performed 8 days later and showed a slight diffuse hypokinesia of left ventricle (LV ejection fraction 51%) with absent focal edema on short-tau inversion recovery images (A) and absent LGE (B), but diffuse alteration of T2 values (B) (56 ms, normal value ≤ 50 ms; C), of native T1 (D) (1084 ms, normal value ≤ 1045 ms E) and of extracellular volume fraction (G) (28%, normal value ≤ 27%; H) with higher values in mid-apical septum and mid-apical anterior wall (arrows in B, D and G). These findings were suggestive for acute myocarditis according to 2018 Lake Louise criteria. Endomyocardial biopsy confirmed these findings, showing diffuse edema and macrophage infiltrate. After 1 month, the patient was discharged with complete resolution of cardiac alteration.

6. Cardiac post-acute COVID-19 syndrome

Cardiac post-acute COVID-19 syndrome (cPACS) is generally defined as the persistence of COVID-19 cardiovascular symptoms or signs for >3–4 weeks after recovery, mainly including lasting chest pain, shortness of breath, palpitations, or troponin levels elevation. Mechanisms responsible for persistence of post-acute cardiac damage are still poorly understood. Possible explanations are chronic inflammatory response for persistent viral reservoirs, autoimmune inflammation due to molecular mimicry, and chronic thromboembolic pulmonary hypertension [19]. In cPACS patients with suspected myocardial involvement, CMR is highly recommended [79] to exclude ischemia, preexisting cardiomyopathies and to assess COVID-19 associated my-
occardial alteration, including myocardial inflammation, scar, and pericardial effusion. Persistent troponin rise was mainly associated to active myocardial inflammation and reported in 14% to 54% of screened cPACS patients [77, 80, 81, 82], with higher prevalence in patients with severe disease [82]. Edema was in fewer cases associated to LGE (8–31%) [80, 81, 82, 83] mainly with non-ischemic pattern involving the infero-lateral wall. Ischemic LGE has been reported less frequently. In a case control study on 90 hospitalized patients with troponin-positive COVID-19 infection [84], CMR performed 2 months after recovery showed post-myocarditis scar in 34% of cases and post-ischemic scar in 17% of cases. Notably, 36% of patients showed adenosine-induced regional perfusion defects. Similar findings were reported by Kotecha et al. [85] on a large series (148) of cPACS patients, with myocarditis-like scar involving three or less myocardial segments as the most frequent finding (26%) (Fig. 4), followed by post ischemic scar (19%); 26% of patients had inducible ischemia. Most patients with inducible ischemia or ischemic scar (66%) had no previous history of coronary artery disease. Despite in cPACS patients LV function seem to be preserved, subclinical alterations were reported in term of strain reduction within 2 and 4 months after moderate to severe COVID-19 infection, respectively [86], mainly associated to edema at early stage and LGE in late stage [86, 87]. Notably, right ventricle dysfunction has been reported as a possible indirect effect of COVID-19 related lung disease and improves over time returning to normality 6 months after recovery [81, 82, 87].

![CMR Image](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335398/)

**Fig. 4**

CMR of a 33-year-old male with persistent palpitation and tachycardia especially during physical activity at 1 year after COVID-19 recovery. Holter ECG documented frequent ectopic ventricular beats. Hence, CMR was performed. CMR showed preserved left and right ventricle ejection fraction, without wall motion alteration. No edema was evident on short-tau inversion recovery images (A) neither on T2 maps (B and C). LGE images (F) showed a thin subepicardial scar on the inferior mid-ventricular wall, associated to increased native T1 (arrows in D, values in E) and ECV values (arrows in H, values in G). These findings were suggestive for post-myocarditis scar.
In asymptomatic patients recovered from mild-to-moderate COVID-19 infection, there is no increased risk in long-term cardiac sequelae. In a prospective study, no differences were identified at CMR performed 6 months post-infection between 74 asymptomatic healthcare workers and age, sex, and ethnicity matched controls [88]. Similarly, Petersen et al. [89] found non-significant CMR alterations in a population of 443 asymptomatic post-COVID patients compared to 1380 matched controls.

7. Cardiac Imaging findings after SARS-CoV-2 vaccine

The COVID-19 vaccines have determined a substantial worldwide decline in morbidity and mortality, with reduction of hospitalization related to severe disease. All approved vaccines have shown to provide benefits that obscure their potential risks across different age groups [90].

Since the beginning of the vaccination program, more reports have been raising concerns for the association of myopericarditis to different types of COVID-19 vaccines 20, 21, 22.

In pre-COVID-19 era, vaccine-related myocarditis or pericarditis had a reported incidence of 0.1%, according to Vaccine Adverse Event Reporting System (VAERS) files collected between 1990 and 2018. Of these, 79% of cases were observed in males [91]. Since COVID-19 vaccines rollout, a rate of 12.6 cases of myocarditis per million doses has been related to the second vaccine shot, in individuals aged between 12 and 39 years.

However, VAERS data collection system cannot be used to determine the real incidence of vaccine adverse events, since it is primarily a safety signal detection and hypothesis-generating system [92]. Certainly, myocarditis has been described as the most frequent vaccine-related adverse event occurring mainly in patients having smallpox vaccination rather than in patients receiving vaccines for single-stranded RNA viruses [93].

However, an association between mRNA COVID-19 vaccines (mRNA-1273 [Moderna] and BNT162b2 [Pfizer-BioNTech]) myocarditis and pericarditis cases has been found, particularly after the second shot of vaccination [94].

Most of the reported cases presented abnormal ECG with ST elevation and elevated cardiac troponin peaking three days after vaccination, usually within 14 days of COVID-19 vaccination [95].

Most subjects had rapid recovery and high antibody levels for SARS-CoV-2 spike protein suggesting effective immunization. Echocardiogram was abnormal in only 40% of cases, with a minimal percentage of patients presenting reduced left ventricular ejection fraction [94]. Conversely, CMR showed abnormalities in all tested patients, depicting findings such as myocardial edema and subepicardial late gadolinium enhancement suggestive of myocarditis.

Recently, Fronza et al. showed that COVID-19 vaccine-related myocarditis has different imaging patterns compared to other causes of myocarditis such as COVID-19-related myocarditis, independently from patients' age or sex and from interval between symptoms onset and imaging [96].
In particular, the authors found that, in vaccine-related myocarditis, right and left ventricular ejection fraction, strain values, and myocardial native T1-value are less altered, while LGE is less extensive and mainly involves the infero-lateral segments compared to other causes of myocarditis (Fig. 5A).

**Fig. 5**

CMR of a 30-year-old male with COVID-19 vaccine-related myocarditis. LGE imaging performed along three-chambers view 5 days after the onset of patient's symptoms (A) shows subepicardial enhancement along the infero-lateral myocardial segments (arrows) with minimal involvement of the anterior wall in the apical region (arrowhead). Cardiac MRI performed 3-months later (B) shows almost complete resolution of myocardial LGE in the same segments.

The etiology of myocardial inflammation following COVID-19 vaccination is still unknown. Different mechanisms have been proposed: i) a delayed hypersensitivity reaction, with sensitization occurring after the first COVID-19 vaccine shot; ii) a mechanism of molecular mimicry between the SARS-CoV-2 spike proteins, encoded by the mRNA vaccines, and cardiomyocyte antigens, which may provoke an immune response in predisposed subjects; iii) a systemic inflammatory response triggered by the antigenic mRNA, leading to myocardial inflammation.

However, almost all reports confirm that symptoms resolution, as well as diagnostic markers and imaging findings normalization, is rapid either with or without treatment (Fig. 5B).

Clinicians should be aware of the existing risk of myocarditis and pericarditis related to COVID-19 vaccination, especially in young male individuals presenting with chest pain shortly after vaccination.

8. Conclusions

Advanced cardiac imaging in COVID-19 provides effective and non-invasive characterization of COVID-19 related cardiovascular manifestations and improves risk stratification, minimizing the use of unnecessary and invasive procedures and speeding-up the diagnostic pathways.
The choice of the most appropriate imaging modality and acquisition protocol needs to be tailored to patient’s clinical features and suspicion. CT angiography allows accurately characterizing vessels involvement. Moreover, independently by the selected protocol, CT can provide a multiplicity of ancillary information useful for a more comprehensive patients’ characterization and risk stratification. CMR has the advantage of enabling accurate myocardial tissue characterization, being able to exclude preexisting cardiomyopathies and to identify subclinical cardiac injury, myocardial inflammation, and abnormalities potentially affecting quality of life or increasing risk of future events.

References


17. Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020;141:1903–1914. doi: 10.1161/CIRCULATIONAHA.120.047349. [PMC free article] [PubMed] [CrossRef] [Google Scholar]


71. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022 doi: 10.1038/S41569-022-00679-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]


73. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022 doi: 10.1038/s41569-022-00679-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]


92. Shimabukuro T.T., Nguyen M., Martin D., DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS) Vaccine. 2015;33:4398–4405. doi: 10.1016/J.VACCINE.2015.07.035. [PMC free article] [PubMed] [CrossRef] [Google Scholar]


94. Bozkurt B., Kamat L, Hotez P.J. Myocarditis with COVID-19 mRNA vaccines. *Circulation.* 2021;144:471–484. doi: 10.1161/CIRCULATIONAHA.121.056135. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
